Literature DB >> 26466009

Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.

Mallory B Shiver1, Fade Mahmoud, Ling Gao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26466009      PMCID： PMC4652581          DOI： 10.1056/NEJMc1507446

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Activation of PI3K signaling in Merkel cell carcinoma.

Authors:  Valentina Nardi; Youngchul Song; Juan A Santamaria-Barria; Arjola K Cosper; Quynh Lam; Anthony C Faber; Genevieve M Boland; Beow Y Yeap; Kristin Bergethon; Vanessa L Scialabba; Hensin Tsao; Jeffrey Settleman; David P Ryan; Darrell R Borger; Atul K Bhan; Mai P Hoang; Anthony J Iafrate; James C Cusack; Jeffrey A Engelman; Dora Dias-Santagata
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

Authors:  David A Fruman; Lewis C Cantley
Journal:  N Engl J Med       Date:  2014-03-13       Impact factor: 91.245

Review 3.  Merkel Cell Carcinoma: Epidemiology, Target, and Therapy.

Authors:  Mathew P Hughes; Matthew E Hardee; Lynn A Cornelius; Laura F Hutchins; Jurgen C Becker; Ling Gao
Journal:  Curr Dermatol Rep       Date:  2014-01-22

4.  A Proteomic Study of Human Merkel Cell Carcinoma.

Authors:  Qiang Shao; Stephanie D Byrum; Linley E Moreland; Samuel G Mackintosh; Aarthi Kannan; Zhenyu Lin; Michael Morgan; Brendan C Stack; Lynn A Cornelius; Alan J Tackett; Ling Gao
Journal:  J Proteomics Bioinform       Date:  2013-11-25

5.  Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Authors:  Dalya R Soond; Roberto Pineiro; Khaled Ali; Thorsten Hagemann; Wayne Pearce; Ee Lyn Lim; Hicham Bouabe; Cheryl L Scudamore; Timothy Hancox; Heather Maecker; Lori Friedman; Martin Turner; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962
  5 in total
  8 in total

Review 1.  [Merkel cell carcinoma: cutaneous manifestation of a highly malignant pre-/pro-B cell neoplasia? : Novel concept about the cellular origin of Merkel cell carcinoma].

Authors:  C M Sauer; E Chteinberg; D Rennspiess; A K Kurz; A Zur Hausen
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

Review 2.  Merkel Cell Carcinoma Therapeutic Update.

Authors:  Nicole M Cassler; Dean Merrill; Christopher K Bichakjian; Isaac Brownell
Journal:  Curr Treat Options Oncol       Date:  2016-07

3.  A rare case of Merkel cell carcinoma with ovarian metastasis.

Authors:  Nicole Keller; Beatrix Haemmerle; Seraina Schmid
Journal:  Gynecol Oncol Rep       Date:  2019-03-20

4.  Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma.

Authors:  Jae Eun Choi; Monique E Verhaegen; Sahr Yazdani; Rohit Malik; Paul W Harms; Doris Mangelberger; Jean Tien; Xuhong Cao; Yuping Wang; Marcin Cieślik; Jonathan Gurkan; Mishaal Yazdani; Xiaojun Jing; Kristin Juckette; Fengyun Su; Rui Wang; Bing Zhou; Ingrid J Apel; Shaomeng Wang; Andrzej A Dlugosz; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2019-02-21       Impact factor: 5.715

5.  Unexpected maspin immunoreactivity in Merkel cell carcinoma.

Authors:  Sabin Gligore Turdean; Simona Gurzu; Ioan Jung; Radu Mircea Neagoe; Daniela Sala
Journal:  Diagn Pathol       Date:  2015-11-25       Impact factor: 2.644

6.  Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma.

Authors:  Emil Chteinberg; Dorit Rennspiess; Ryan Sambo; Samantha Tauchmann; Nicole W J Kelleners-Smeets; Véronique Winnepenninckx; Ernst-Jan Speel; Anna Kordelia Kurz; Martin Zenke; Axel Zur Hausen
Journal:  Oncotarget       Date:  2018-07-03

7.  Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.

Authors:  Bin Fang; Aarthi Kannan; Stephanie Zhao; Quy H Nguyen; Samuel Ejadi; Maki Yamamoto; J Camilo Barreto; Haibo Zhao; Ling Gao
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.996

8.  An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response.

Authors:  Todd C Knepper; Robyn A Panchaud; Elnara Muradova; Leah Cohen; James A DeCaprio; Nikhil I Khushalani; Kenneth Y Tsai; Andrew S Brohl
Journal:  Cancer Med       Date:  2021-07-16       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.